pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›deramiocel
drug · cell
save

deramiocel

pre_registrationupdated 7mo ago
by $CAPR CAPRICOR THERAPEUTICS, INC.🔗 ChEMBL
community read0 votes

Cell drug with a maximum clinical stage of Phase 2, with 1 investigational indication.

indications

indications
Duchenne Muscular Dystrophy

all catalysts(0)

nothing on the calendar yet

Trials studying deramiocel

  • phase2Open-label Extension of the HOPE-2 Trialactive not recruitingn=13
  • phase3A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophyactive not recruitingn=106

News(10)

  • Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trial
    Capricor Therapeutics’ deramiocel cell therapy was rejected for a second time by the FDA on Friday, despite the company's pivot to a narrower indication within Duchenne muscular dystrophy. In a
    endpoints · 5h ago
  • STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming
    The FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.
    stat · 7h ago
  • Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears
    Awaiting a decision on Nov. 22 for its embattled Duchenne muscular dystrophy cell therapy deramiocel, Capricor has reduced its workforce by 10% and slowed programs not directly related to deramioce…
    biospace · 9d ago
  • Capricor ramps up manufacturing spend ahead of FDA decision for DMD therapy
    Less than two weeks away from a highly anticipated FDA ruling on its cell therapy for Duchenne muscular dystrophy, Capricor Therapeutics has reported increased investment in its San Diego plant to…
    biospace · 9d ago
  • Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
    Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…
    biospace · 9d ago
  • Capricor, NextCure shed light on recent layoffs as they gear up for approval decision, merger
    Capricor and NextCure have shed light on recent rounds of layoffs, as the biotechs brace for a hoped-for drug approval and merger, respectively.
    fiercebiotech · 10d ago
  • FDA's rare disease framework faces its first real test in Capricor’s DMD drug
    Last month, the FDA committed to designing a "fit-for-purpose" framework for regulating rare disease therapies based on patient need and realistically attainable evidence. With the upcoming decisio…
    biospace · 10d ago
  • Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
    Also lined up are target action dates for Sanofi’s Gaucher disease therapy, GSK’s lung cancer medicine and BridgeBio’s muscular dystrophy drug.
    biospace · 14d ago
  • FDA's latest rare disease framework seeks to prioritize consistency in flexibility
    Following several recent initiatives, the FDA's newest rare disease framework sets out to standardize the agency's approach to scientific evidence and bring rare disease therapies to patients faster.
    biospace · 1mo ago
  • US senators grill FDA nominee Overton on ability to ‘stand up’ to Trump
    In Thursday’s Senate committee meeting, FDA commissioner nominee Heidi Overton was repeatedly questioned about her ability to retain the FDA’s independence under President Donald Trump, as well as…
    biospace · 1mo ago
view all news mentions →
generic
deramiocel
indication
Cardiomyopathy
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 18m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?